|
WO2021041964A1
|
|
Conjugated inhibitors of dna damage response
|
|
WO2021026494A1
|
|
Steam sterilization of hydrogels crosslinked by beta-eliminative linkers
|
|
WO2020219943A1
|
|
Slow-release cytokine conjugates
|
|
WO2020206358A1
|
|
Improved conjugation linkers
|
|
WO2019152672A1
|
|
Aseptic method and apparatus to prepare sterile formulations of drug-linked hydrogel microspheres
|
|
CA3087628A1
|
|
Synergistic cancer treatment
|
|
AU2017234680A1
|
|
Extended release conjugates of exenatide analogs
|
|
WO2016025752A1
|
|
Reagents for thiol conjugation and conjugates formed therefrom
|
|
CN106232131A
|
|
Somatostatin and the conjugate of its analog
|
|
CA2925132A1
|
|
Slow-release conjugates of sn-38
|
|
EP2925256A1
|
|
Sealants having controlled degradation
|
|
WO2013059323A1
|
|
Peg conjugates of exenatide
|
|
CA2848142A1
|
|
Hydrogels with biodegradable crosslinking
|
|
WO2013036857A1
|
|
Sulfone linkers
|
|
WO2011140376A1
|
|
Controlled drug release from dendrimers
|
|
CN103025164A
|
|
Controlled drug release from solid supports
|
|
EP2566335A1
|
|
Controlled release of active compounds from macromolecular conjugates
|
|
CN102076331A
|
|
Prodrugs and drug-macromolecule conjugates having controlled drug release rates
|
